

Enantioselective Synthesis of Diaryl Aziridines Using Tetrahydrothiophene-Based Chiral Sulfides as Organocatalysts

Meng-Ting Huang[†], Hsin-Yi Wu[‡], and Rong-Jie Chein *^{†‡}

[†]Department of Chemistry, National Taiwan Normal University, Taipei, Taiwan 11677

[‡]Institute of Chemistry, Academia Sinica, 128 Academia Road Sec. 2, Nankang, Taipei, Taiwan 11529.
Fax: 886-2-2783-1237; Tel: 886-2-2789-8526; E-mail: rjchein@chem.sinica.edu.tw

Supporting Information

Table of content	Page
Experimental Procedures and Characterization Data -----	S2
References -----	S25
HPLC analysis -----	S26
¹ H and ¹³ C NMR Spectra-----	S36

Experimental Procedures and Characterization Data:


General information:

All reactions were carried out under an inert atmosphere unless mentioned otherwise, and standard syringe-septa techniques were followed. Solvents were freshly dried and purified by conventional methods prior to use. The progress of all the reactions were monitored by TLC, using TLC glass plates precoated with silica gel 60 F₂₅₄ (Merck). Column chromatography was performed on silica gel Geduran® Si 60 (Merck). Optical rotation values were measured with Jasco P-2000 polarimeter, and IR spectra were recorded with Thermo Nicolet iS-5 FT-IR spectrophotometer, ν_{max} in cm⁻¹. ¹H and ¹³C NMR spectra were recorded with Bruker AV-III 400 MHz, Bruker AV-400, or AV-500 MHz spectrometers and chemical shifts were measured in δ (ppm) with residual solvent peaks as internal standards (CDCl_3 , δ 7.26 ppm in ¹H NMR, δ 77 ppm in ¹³C NMR). Coupling constants J , measured in Hz. HR FAB (LR FAB) and HR EI (LR EI)-mass spectra were recorded on a JMS-700 double focusing mass spectrometer (JEOL, Tokyo, Japan) with a resolution of 8000(3000) (5% valley definition) and HR (LR) ESI (Electrospray)-mass spectra were recorded using dual ionization ESCi® (ESI/APCI) source options, Waters LCT premier XE (Waters Corp., Manchester, UK). Melting points were recorded on Buchi 520 apparatus. The determination of ee was performed *via* chiral phase HPLC analysis using Agilent 1200 series HPLC workstation.

General procedure for synthesis of Alcohols 4a-4c:


To a solution of aryl magnesium bromide (2 mmol) freshly prepared from magnesium powder and aryl bromide in THF (4 mL) was added a solution of ethyl 5-bromo-2-methylvalerate (500 mg, 2.39 mmol) in THF (2 mL) dropwisely at 0 °C. After stirring for 12 h at room temperature, the reaction mixture was quenched with sat. NH_4Cl (5 mL) at 0 °C and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with sat. NaHCO_3 (10 mL × 2) and brine, dried over Na_2SO_4 , and concentrated in *vacuo*. The residue was purified by flash column chromatography (EtOAc/hexane) to give the pure product.

5-Bromo-1,1-diphenylpentan-1-ol (4a)¹




Colorless liquid; Yield - 90%; R_f (10% EtOAc/hexane) 0.3; Prepared as shown in general procedure. ¹**H NMR** (400 MHz, CDCl_3) δ 7.48–7.26 (m, 10H), 3.36 (t, J = 7.0 Hz, 2H), 2.42 (s, 1H), 2.35–2.31 (m, 2H), 1.91 (dt, J = 14.5, 7.1 Hz, 2H), 1.52–1.44 (m, 2H); ¹³**C NMR** (100 MHz, CDCl_3) δ 146.7, 128.0, 126.7, 125.9, 77.9, 40.8, 33.3, 32.9, 22.4.

5-Bromo-1,1-bis(3,5-dimethylphenyl)pentan-1-ol (4b)



Colorless liquid; Yield - 95%; R_f (10% EtOAc/hexane) 0.4; Prepared as shown in general procedure. **IR** (neat): 3549, 3005, 2946, 2916, 2863, 1599, 1453, 1376, 1247, 1149, 1038, 851, 742, 719 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.01 (s, 4H), 6.87 (s, 2H), 3.38 (t, $J = 7.0$ Hz, 2H), 2.29 (s, 12H), 2.25–2.21 (m, 2H), 2.02 (s, 1H), 1.91 – 1.87 (m, 2H), 1.47 – 1.39 (m, 2H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 146.9, 137.5, 128.5, 123.7, 77.9, 41.1, 33.4, 33.2, 22.6, 21.5; **ESI-HRMS** (m/z): Calcd for $\text{C}_{21}\text{H}_{27}\text{BrONa}$ $[(\text{M}+\text{Na})^+]$ 397.1143, found $[(\text{M}+\text{Na})^+]$ 397.1144.

1,1-Bis(3,5-bis(trifluoromethyl)phenyl)-5-bromopentan-1-ol (4c)




Colorless liquid; Yield - 85%; R_f (10% EtOAc/hexane) 0.18; Prepared as shown in general experimental procedure. **IR** (neat): 3518, 3097, 2952, 2868, 1624, 1466, 1278, 1132, 900, 844, 710, 682 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.89 (s, 4H), 7.82 (s, 2H), 3.40 (t, $J = 6.4$ Hz, 2H), 2.52 (s, 1H), 2.40 – 2.36 (m, 2H), 1.97 – 1.90 (m, 2H), 1.50 – 1.42 (m, 2H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 147.8, 132.2 (q, $J = 33.3$ Hz), 126.0, 123.1 (q, $J = 271.2$ Hz), 121.9, 40.7, 32.9, 32.1, 21.8; **ESI-HRMS** (m/z): Calcd for $\text{C}_{21}\text{H}_{14}\text{BrF}_{12}\text{O}$ $[(\text{M}-\text{H})^-]$ 589.0036, found $[(\text{M}-\text{H})^-]$ 589.0042.

General procedure for synthesis of Olefins 5a-5c:


A stirred solution of diaryl alcohol (1 mmol) and *p*-TsOH (5% wt) in toluene (4 mL) was heated to 70 °C for 3 h. After cooling down to room temperature, the reaction mixture was diluted with DI water (10 mL), extracted with EtOAc (10 mL × 3), dried over Na_2SO_4 , and concentrated in *vacuo*. The residue was purified by flash column chromatography (hexane) to give the pure product.

5,5-Diphenyl-4-pentenyl bromide (5a)¹




Colorless oil; Yield - 88%; R_f (hexane) 0.25; Prepared as shown in general procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.39–7.16 (m, 10H), 6.04 (t, $J = 7.4$ Hz, 1H), 3.37 (t, $J = 6.9$ Hz, 2H), 2.26 (dd, $J = 14.7, 7.4$ Hz, 2H), 2.03–1.95 (m, 2H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 143.0, 142.4, 139.8, 129.8, 128.2, 128.1, 127.5, 127.2, 127.0, 33.1, 33.0, 28.4.

5,5'-(5-Bromopent-1-ene-1,1-diyl)bis(1,3-dimethylbenzene) (**5b**)



Colorless oil; Yield - 92%; R_f (hexane) 0.45; Prepared as shown in general procedure. **IR** (neat): 3007, 2916, 1862, 1654, 1599, 1437, 1195, 850, 731 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 6.96 (s, 1H), 6.89 (s, 1H), 6.86 (s, 2H), 6.79 (s, 2H), 5.96 (t, $J = 7.6$ Hz, 1H), 3.41 (t, $J = 6.8$ Hz, 2H), 2.34 (s, 6H), 2.28 (s, 6H), 2.64 – 2.27 (m, 2H), 2.05 – 1.99 (m, 2H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 143.4, 142.7, 139.9, 137.5, 137.5, 137.5, 128.7, 128.6, 128.5, 127.5, 127.4, 127.0, 127.0, 125.1, 125.1, 33.2, 28.4, 21.3, 21.3; **EI-HRMS** (m/z): Calcd for $\text{C}_{21}\text{H}_{25}\text{Br}$ $[(\text{M})^+]$ 356.1140, found $[(\text{M})^+]$ 356.1139.

5,5'-(5-Bromopent-1-ene-1,1-diyl)bis(1,3-bis(trifluoromethyl)benzene) (**5c**)




Colorless oil; Yield - 95%; R_f (10% EtOAc/hexane) 0.55; Prepared as shown in general procedure. **IR** (neat): 3089, 2933, 2868, 1614, 1468, 1373, 1279, 1128, 901, 708, 721 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.93 (s, 1H), 7.81 (s, 1H), 7.65 (s, 2H), 7.58 (s, 2H), 6.30 (t, $J = 7.6$ Hz, 1H), 3.40 (t, $J = 6.4$ Hz, 2H), 2.35 – 2.29 (m, 2H), 2.10 – 2.03 (m, 2H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 143.0, 138.4, 134.1, 132.9, 132.6, 132.3, 132.0, 131.6, 129.8, 127.0, 124.4, 122.2, 121.7, 121.6, 32.3, 32.1, 28.4; **EI-HRMS** (m/z): Calcd for $\text{C}_{21}\text{H}_{13}\text{BrF}_{12}$ $[(\text{M})^+]$ 572.0009, found $[(\text{M})^+]$ 571.9999.

General procedure for synthesis of Epoxides 6a-6c:


A combined solution of 5,5-diaryl-4-pentenyl bromide (1.0 mmol) in CH₃CN/dimethoxymethane (1:2, v/v, 7.5 mL), and Na₂B₄O₇·10H₂O (190.5 mg, 0.5 mmol), tetrabutylammonium hydrogen sulfate (13.6 mg, 0.04 mmol), and Shi catalyst² (129 mg, 0.5 mmol) in a buffer solution (4×10^{-4} M aqueous Na₂(EDTA), 5 mL) was cooled to -5 °C and stirred in an ice bath. A solution of Oxone (1.5 g, 0.5 mmol) in aqueous Na₂(EDTA) (4×10^{-4} M, 6.25 mL) and a solution of K₂CO₃ (1.6 g, 10.35 mmol) in DI water (6.25 mL) were respectively added dropwisely through addition syringes respectively over a period of 3 h at -5 °C. Upon completion of the addition, the reaction was stirred for another 1 h at the same temperature. After dilution with DI water (20 mL), the resulting mixture was extracted with hexane (20 mL × 2), dried over Na₂SO₄, and concentrated in *vacuo*. The residue was purified by flash column chromatography (EtOAc/hexane, 1:40 to 1:25) to afford the pure product.

3-(3-Bromopropyl)-2,2-diphenyloxirane (6a)¹



Colorless liquid; Yield - 94%; R_f (5% EtOAc/hexane) 0.32; Prepared as shown in general procedure. ¹**H NMR** (400 MHz, CDCl₃) δ 7.40–7.23 (m, 10H), 3.44–3.30 (m, 3H), 2.13–1.94 (m, 2H), 1.69 (ddd, $J = 14.0, 9.8, 5.3$ Hz, 1H), 1.33 (m, 1H); ¹³**C NMR** (100 MHz, CDCl₃) δ 140.7, 137.2, 128.2, 128.1, 127.9, 127.8, 127.6, 126.9, 66.1, 65.4, 32.9, 29.6, 28.2; enantioselectivity was determined by HPLC analysis (Chiralcel-OJ, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 4:1); retention time: 19.4 min (enantiomer) and 35.8 min (major).


3-(3-Bromopropyl)-2,2-bis(3,5-dimethylphenyl)oxirane (6b)



Colorless liquid; Yield - 92%; R_f (5% EtOAc/hexane) 0.5; Prepared as shown in general procedure. **IR** (neat): 3005, 2963, 2916, 2863, 1604, 1545, 1248, 1203, 849, 728 cm⁻¹; ¹**H NMR** (400 MHz, CDCl₃) δ 7.00 (s, 2H), 6.96 (s, 2H), 6.95 (s, 1H), 6.94 (s, 1H), 3.48 – 3.35 (m, 3H), 2.32 (s, 6H), 2.29 (s, 6H), 2.12 – 2.00 (m, 2H), 1.71 (m, 1H), 1.35 (m, 1H); ¹³**C NMR** (100 MHz, CDCl₃) δ 140.9, 137.8, 137.6, 137.4, 129.4,

129.3, 125.5, 124.7, 66.4, 65.1, 32.9, 29.8, 28.2, 21.3, 21.3; **HRMS (FAB⁺, magnetic sector)** (*m/z*): Calcd for C₂₁H₂₆BrO [(M+H)⁺] 373.1167, found [(M+H)⁺] 373.1162; enantioselectivity was determined by HPLC analysis (Chiralpak-AD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19:1); retention time: 3.6 min (enantiomer) and 4.1 min (major).

2,2-Bis(3,5-bis(trifluoromethyl)phenyl)-3-(3-bromopropyl)oxirane (6c)




Colorless liquid; Yield - 80% (based on recovered starting material); *R*_f (5% EtOAc/hexane) 0.38; Prepared as shown in general procedure. **IR** (neat): 3094, 2970, 2852, 1623, 1466, 1389, 1279, 1132, 901, 709, 681 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.89 (s, 2H), 7.87 (s, 1H), 7.76 (s, 2H), 3.46 – 3.38 (m, 3H), 2.21 – 1.97 (m, 2H), 1.78 (m, 1H), 1.27 (m, 1H); **¹³C NMR** (125 MHz, CDCl₃) δ 141.6, 138.4, 132.5 (q, *J*_{C-F} = 33.8 Hz), 128.0, 126.9, 122.9 (q, *J*_{C-F} = 273.4 Hz), 122.8, 122.7, 66.3, 64.5, 32.2, 29.2, 27.8; **HRMS (FAB⁺, magnetic sector)** (*m/z*): Calcd for C₂₁H₁₃BrF₁₂O [(M)⁺] 587.9958 found [(M)⁺] 587.9951; enantioselectivity was determined by HPLC analysis (Chiralpak-IA, 0.3 mL/min, 220 nm, hexane); retention time: 15.0 min (major) and 16.0 min (enantiomer).

General procedure for synthesis of ((S)-Thiolan-2-yl)diarylmethanol 1a-1c:


A mixture of the (*R*)-3-(3-bromopropyl)-2,2-diaryloxirane (3.0 mmol) and Na₂S·9H₂O (1.4 g, 6.0 mmol) in 95% ethanol (10.5 mL) was sonicated at 10–25 °C for 24 h (conversion is monitored by the crude ¹H NMR). Upon removal of ethanol, the crude residue was diluted with DI water (20 mL) and CH₂Cl₂ (20 mL). The aqueous layer was extracted with CH₂Cl₂ (10 mL × 2). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in *vacuo*. The residue was purified by flash column chromatography (EtOAc/hexane, 1:99 to 1:20) and recrystallized from hexane or light petroleum ether to afford the pure product.

((S)-Thiolan-2-yl)diphenylmethanol (1a)¹




Yield - 95%; R_f (2% EtOAc/hexane) 0.28; Prepared as shown in general procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.54–7.51 (m, 2H), 7.44–7.41 (m, 2H), 7.30–7.22 (m, 4H), 7.21–7.12 (m, 2H), 4.66 (dd, J = 8.4, 6.8 Hz, 1H), 3.53 (s, 1H), 2.86–2.83 (m, 2H), 2.16 (m, 1H), 1.87–1.73 (m, 2H), 1.62 (m, 1H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 148.0, 145.0, 128.2, 128.0, 127.1, 126.5, 126.1, 125.4, 77.9, 59.5, 33.4, 31.7; enantioselectivity was determined by HPLC analysis (Chiralpak-AD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19/1); retention time 6.0 min (enantiomer) and 8.5 min (major).

(S)-Bis(3,5-dimethylphenyl)(tetrahydrothiophen-2-yl)methanol (1b)



Yield - 92%; R_f (2% EtOAc/hexane) 0.32; Prepared as shown in general procedure. **IR** (neat): 3468, 2918, 2860, 1601, 1441, 1146, 851, 755, 732 cm^{-1} ; **$^1\text{H NMR}$** (500 MHz, CDCl_3) δ 7.19 (s, 2H), 7.11 (s, 2H), 6.87 (s, 1H), 6.83 (s, 1H), 4.68 (t, J = 2 Hz, 1H), 3.52 (s, 1H), 2.86 – 2.84 (m, 2H), 2.35 (s, 6H), 2.31 (s, 6H), 2.20 (m, 1H), 1.87 – 1.78 (m, 2H), 1.67 (m, 1H); **$^{13}\text{C NMR}$** (125 MHz, CDCl_3) δ 148.1, 145.0, 137.4, 137.3, 128.7, 128.1, 123.8, 123.1, 77.7, 59.7, 33.4, 31.8, 21.5; **ESI-HRMS** (m/z): Calcd for $\text{C}_{21}\text{H}_{26}\text{OSNa}$ [(M+Na) $^+$] 349.1602 found [(M+Na) $^+$] 349.1608; enantioselectivity was determined by HPLC analysis (Chiralpak-AD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 199/1); retention time: 10.2 min (enantiomer) and 14.7 min (major).

(S)-Bis(3,5-bis(trifluoromethyl)phenyl)(tetrahydrothiophen-2-yl)methanol (1c)




Yield - 90%; R_f (5% EtOAc/hexane) 0.49; Prepared as shown in general procedure. **IR** (neat): 3542, 2942, 2869, 1642, 1372, 1278, 1132, 900, 682 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 8.00 (s, 2H), 7.90 (s, 2H), 7.81 (s, 1H), 7.78 (s, 1H), 4.67 (m, 1H), 3.99 (s, 1H), 2.95 – 2.88 (m, 2H), 2.24 (m, 1H), 1.90 (m, 1H), 1.75 (m, 1H), 1.63 (m, 1H); **$^{13}\text{C NMR}$** (125 MHz, CDCl_3) δ 148.9, 146.1, 132.1 (qd, $J_{\text{C-F}} = 33.8$ Hz), 126.4, 125.6, 122.9 (q, $J_{\text{C-F}} = 273.4$ Hz), 122.1, 121.7, 58.8, 33.7, 31.7, 31.7; **EI-HRMS** (m/z): Calcd for $\text{C}_{21}\text{H}_{13}\text{F}_{12}\text{OS}$ [(M-H) $^+$] 541.0496, found [(M-H) $^+$] 541.0499; enantioselectivity was determined by HPLC analysis (Chiralcel-OD-H, 0.4 mL/min, 220 nm, hexane); retention time: 13.4 min (enantiomer) and 14.8 min (major).

General procedure for synthesis of (*S*)-2-((Benzylxy)diaryl methyl)tetrahydrothiophene 2a-2c:


To a stirred solution of ((*S*)-thiolan-2-yl)diaryl methanol (1.9 mmol) in DMF (3.7 mL) at 0 °C was added sodium hydride (148 mg, 3.7 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. Benzyl bromide (0.27 mL, 2.2 mmol) was then slowly added to the reaction mixture. After 16 h, the reaction mixture was quenched with sat. NH₄Cl (5 mL) at 0 °C, extracted with Et₂O (5 mL × 3), dried over Na₂SO₄, and concentrated in *vacuo*. The residue was purified by flash column chromatography (EtOAc/hexane, 1:49) to give the pure product.

(*S*)-2-((Benzylxy)diphenylmethyl)tetrahydrothiophene (2a)¹




White solid; Yield - 92%; R_f (10% EtOAc/hexane) 0.5; Prepared as shown in general experimental procedure.). **¹H NMR** (400 MHz, CDCl₃) δ 7.57–7.55 (m, 2H), 7.44 (d, J = 7.2 Hz, 2H), 7.34–7.16 (m, 11H), 4.66 (t, J = 7.2 Hz, 1H), 4.38 (d, J = 11.6 Hz, 1H), 4.21 (d, J = 11.5 Hz, 1H), 2.63 (m, 1H), 2.32 (ddd, J = 10.1, 8.2, 6.1 Hz, 1H), 1.98 (td, J = 12.7, 6.0 Hz, 1H), 1.84 (m, 1H), 1.64 (m, 1H), 1.34 (tt, J = 11.9, 5.9 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 129.3, 128.8, 128.0, 127.4, 127.2, 127.1, 127.0, 126.9, 126.9, 85.9, 65.5, 53.8, 32.6, 31.6, 30.2.

(*S*)-2-((Benzylxy)bis(3,5-dimethylphenyl)methyl)tetrahydrothiophene (2b)



Colorless liquid; Yield -78% (based on recovered starting material); R_f (10% EtOAc/hexane) 0.53; Prepared as shown in general experimental procedure. **IR** (neat): 3058, 1604, 1512, 1205, 1123, 957, 726, 694, 526 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.37 – 7.31 (m, 3H), 7.25 – 7.17 (m, 4H), 7.05 (s, 2H), 6.92 (s, 1H), 6.88 (s, 1H), 4.59 (t, J = 6.9 Hz, 1H), 4.44 (d, J = 9.6 Hz, 1H), 4.38 (d, J = 9.6 Hz, 1H), 2.70 (m, 1H), 2.43 (m, 1H), 2.30 (s, 6H), 2.28 (s, 6H), 1.96 (m, 1H), 1.84 (m, 1H), 1.70 (m, 1H), 1.50 (m, 1H); **¹³C NMR** (125 MHz, CDCl₃) δ 143.7, 141.7, 136.7, 136.3, 130.8, 128.8, 128.7, 128.4, 128.1, 127.7, 127.2, 126.9, 126.5, 65.9, 54.7, 32.8, 31.1, 30.4, 21.6; **ESI-HRMS** (*m/z*): Calcd for C₂₈H₃₂OSNa [(M+Na)⁺] 439.2072, found [(M+Na)⁺] 439.2070.


(S)-2-((Benzyoxy)bis(3,5-bis(trifluoromethyl)phenyl)methyl)tetrahydrothiophene (2c)



Colorless liquid; Yield - 82% (based on recovered starting material); R_f (10% EtOAc/hexane) 0.5; Prepared as shown in general experimental procedure. **IR** (neat): 3092, 2936, 2868, 1623, 1466, 1374, 1279, 1133, 900, 710, 682 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 8.02 (s, 2H), 7.89 (s, 1H), 7.88 (s, 1H), 7.85 (s, 2H), 7.35 – 7.29 (m, 3H), 7.20 – 7.19 (m, 2H), 4.66 (t, $J = 7.2$ Hz, 1H), 4.32 (d, $J = 10.8$ Hz, 1H), 4.27 (d, $J = 11.2$ Hz, 1H), 2.78 (m, 1H), 2.38 (m, 1H), 2.15 (m, 1H), 1.80 (m, 1H), 1.63 (m, 1H), 1.44 (m, 1H); **$^{13}\text{C NMR}$** (125 MHz, CDCl_3) δ 144.7, 143.2, 137.1, 131.3 (dq, $J_{\text{C-F}} = 84.3$ Hz, $J_{\text{C-F}} = 33.3$ Hz), 129.3, 129.0, 128.6, 128.0, 127.3, 123.2 (dq, $J_{\text{C-F}} = 271.1$ Hz, $J_{\text{C-F}} = 20.6$ Hz), 122.5, 122.1, , 85.6, 66.3, 52.4, 33.1, 31.5, 30.2; **HRMS (FAB⁺, magnetic sector)** (m/z): Calcd for $\text{C}_{28}\text{H}_{21}\text{F}_{12}\text{OS}$ [(M+H)⁺] 633.1122, found [(M+H)⁺] 633.1116.


General procedure for synthesis of Imines

(E)-N-Benzylidene-4-methylbenzenesulfonamide (7a)³



To a solution of *p*-toluenesulfonamide (744 mg, 4.7 mmol), activated 4 \AA MS (1 g) and catalytic amount of Amberlyst® 15 (20 mg) in dry toluene was added benzaldehyde (500 mg, 4.7 mmol) and heated at 130 °C in a sealed tube for 12 h. The reaction mixture was filtered through Celite® and concentrated in *vacuo*. The residue was recrystallized by EtOAc to afford the pure product as a colorless solid (1.0 g, 86%). R_f (30% EtOAc/hexane) 0.35; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.03 (s, 1H), 7.94 – 7.88 (m, 4H), 7.62 (t, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 8$ Hz, 2H), 7.35 (t, $J = 5$ Hz, 2H), 2.44 (s, 3H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 170.1, 144.6, 134.9, 132.5, 131.3, 129.8, 129.1, 128.1, 21.6

(E)-*tert*-Butyl benzylidenecarbamate (7b)³




At room temperature, to a mixture of *tert*-butyl carbamate (1.1 g, 10 mmol) · formic acid (0.66 mL, 20 mmol) and the sodium salt of 4-toluenensulfonic acid (3.5 g, 20 mmol) in $\text{H}_2\text{O}/\text{MeOH}$ (2/1, 28 mL) was added neat

benzaldehyde (1.5 mL, 15 mmol). The result white slurry was allowed to stir for 1 d. The thus-formed white solid was filtered over a sintered glass funnel, washed with Et₂O (25 mL × 3), and dried under vacuum, affording the analytically pure intermediate as a white solid (1.9 g, 55 %).

Under inert atmosphere, a flame-dried round-bottom flask was charged with that intermediate (180 mg, 0.5 mmol), anhydrous K₂CO₃ (414 mg, 3.0 mmol), and Na₂SO₄ (531 mg, 3.75 mmol) in THF (0.1 M, 5 mL) and heated at reflux for 15 h. The reaction mixture was then allowed to cool to room temperature, followed by filtration through a pad of Celite®. Evaporation of the collected organic solvent under reduced pressure afforded the analytically pure product (40 mg, 95 %). *R*_f (5% EtOAc/hexane) 0.23; ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 7.93 – 7.90 (m, 2H), 7.56 (m, 1H), 7.49 – 7.45 (m, 2H), 1.59 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 162.6, 134.1, 133.5, 130.2, 128.9, 82.3, 27.9


(E)-N-Arylmethylene-*P,P*-diphenylphosphinic amide 7c – 7q:



To a solution of NH₂OH·HCl (1.1 g, 16.2 mmol) and NaOAc (1.1 g, 13.76 mmol) in H₂O (12.1 mL) was added benzaldehyde (0.96 mL, 9.4 mmol) and stirred for 3 h. After completion of the reaction, extracted with Et₂O (10 mL × 3), washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexane, 1:19) to give the pure oxime.

To a solution of oxime (0.1 mL, 1.0 mmol) in CH₂Cl₂/hexane (1:1, 5 mL) triethylamine (0.20 mL, 1.1 mmol) was added at -40 °C and stirred for 10 min, diphenylphosphinic chloride (0.15 mL, 1.1 mmol) was slowly added to the reaction at same temperature. The reaction mixture was gradually allowed to warm to room temperature and stirred overnight, evaporated under reduced pressure. The residue was purified by flash column chromatography (EtOAc/hexane, 1:49) to give the pure product.


(E)-N-Benzylidene-*P,P*-diphenylphosphinic amide (7c)³



White solid; Yield - 50%; *R*_f (50% EtOAc/hexane) 0.3; Prepared as shown in general experimental procedure. ¹H NMR (400 MHz, CDCl₃) δ 9.32 (d, *J* = 32.1 Hz, 1H), 8.03 – 7.89 (m, 6H), 7.55 – 7.40 (m,


9H); **¹³C NMR** (100 MHz, CDCl₃) δ 173.6 (d, *J*_{C-P} = 7.6 Hz), 135.7 (d, *J*_{C-P} = 24.7 Hz), 133.50, 132.8 (d, *J*_{C-P} = 126.7 Hz), 131.7 (d, *J*_{C-P} = 1.9 Hz), 131.4 (d, *J*_{C-P} = 9.1 Hz), 130.0, 128.8, 128.3 (d, *J*_{C-P} = 12.5 Hz).

(E)-N-(4-(Trifluoromethyl)benzylidene)-P,P-diphenylphosphinic amide (7d)⁴




White solid; Yield - 72%; *R*_f (50% EtOAc/hexane) 0.45; Prepared as shown in general experimental procedure. **¹H NMR** (400 MHz, CDCl₃) δ 9.38 (d, *J* = 31.5 Hz, 1H), 8.13 (d, *J* = 8.2 Hz, 2H), 7.99 – 7.90 (m, 4H), 7.77 (d, *J* = 8.2 Hz, 2H), 7.56 – 7.43 (m, 6H); **¹³C NMR** (100 MHz, CDCl₃) δ 172.2 (d, *J*_{C-P} = 7.5 Hz), 138.6 (d, *J*_{C-P} = 24.7 Hz), 134.8 (q, *J*_{C-F} = 32.6 Hz), 133.0, 132.1 (d, *J*_{C-P} = 2.1 Hz), 131.7, 131.6 (d, *J*_{C-P} = 9.2 Hz), 130.3, 128.6 (d, *J*_{C-P} = 12.6 Hz), 126.0 (d, *J*_{C-P} = 3.4 Hz), 123.6 (q, *J*_{C-F} = 270 Hz).

(E)-N-(4-Chlorobenzylidene)-P,P-diphenylphosphinic amide (7e)⁴




White solid; Yield - 58%; *R*_f (50% EtOAc/hexane) 0.33; Prepared as shown in general experimental procedure. **¹H NMR** (400 MHz, CDCl₃) δ 9.28 (d, *J* = 31.7 Hz, 1H), 7.96 – 7.90 (m, 6H), 7.53 – 7.43 (m, 8H); **¹³C NMR** (125 MHz, CDCl₃) δ 172.3 (d, *J*_{C-P} = 7.3 Hz), 140.0, 134.3 (d, *J*_{C-P} = 25.2 Hz), 132.8 (d, *J*_{C-P} = 151.6 Hz), 132.1, 131.9, 131.6 (d, *J*_{C-P} = 9.07 Hz), 131.3, 129.4, 128.5 (d, *J*_{C-P} = 12.6 Hz).

(E)-N-(4-Fluorobenzylidene)-P,P-diphenylphosphinic amide (7f)⁵




White solid; Yield - 78%; *R*_f (50% EtOAc/hexane) 0.41; Prepared as shown in general experimental procedure. **¹H NMR** (400 MHz, CDCl₃) δ 9.28 (d, *J* = 31.8 Hz, 1H), 8.07 – 7.99 (m, 2H), 7.98 – 7.88 (m, 4H), 7.54 – 7.41 (m, 6H), 7.23 – 7.15 (m, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 172.1 (d, *J*_{C-P} = 7.4 Hz), 166.1 (d, *J*_{C-F} = 254.3 Hz), 133.5, 132.5 (d, *J*_{C-P} = 9.4 Hz), 132.2, 131.8 (d, *J*_{C-F} = 2.1 Hz), 131.6 (d, *J*_{C-P} = 9.2 Hz), 128.5 (d, *J*_{C-P} = 12.5 Hz), 116.3 (d, *J*_{C-P} = 22 Hz).

(E)-N-(4-Methoxybenzylidene)-P,P-diphenylphosphinic amide (7g)⁶




White solid; Yield - 55%; R_f (50% EtOAc/hexane) 0.2; Prepared as shown in general experimental procedure.
¹H NMR (400 MHz, CDCl₃) δ 9.23 (d, J = 32.1 Hz, 1H), 8.02 – 7.88 (m, 6H), 7.55 – 7.38 (m, 6H), 6.99 (d, J = 8.7 Hz, 2H), 3.87 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 172.6 (d, J_{C-P} = 7.4 Hz), 164.1, 133.4 (d, J_{C-P} = 127.2 Hz), 132.3, 131.6, 131.5, 129.1 (d, J_{C-P} = 25.4 Hz), 128.4 (d, J_{C-P} = 12.5 Hz), 114.3, 55.5.

(E)-N-(3-Methoxybenzylidene)-P,P-diphenylphosphinic amide (7h)⁴




Colourless oil; Yield - 64%; R_f (50% EtOAc/hexane) 0.3; Prepared as shown in general experimental procedure.
¹H NMR (400 MHz, CDCl₃) δ 9.28 (d, J = 31.9 Hz, 1H), 7.96 – 7.91 (m, 4H), 7.58 – 7.40 (m, 9H), 7.13 (dd, J = 8.2, 2.6 Hz, 1H), 3.89 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 173.7 (d, J_{C-P} = 7.7 Hz), 160.0, 137.1, 132.9 (d, J_{C-P} = 128.1 Hz), 131.8 (d, J_{C-P} = 2.9 Hz), 131.6 (d, J_{C-P} = 9.4 Hz), 130.0, 128.6 (d, J_{C-P} = 12.5 Hz), 123.7, 120.0, 113.6, 55.5.

(E)-N-(2-Methoxybenzylidene)-P,P-diphenylphosphinic amide (7i)⁷




White solid; Yield - 61%; R_f (50% EtOAc/hexane) 0.48; Prepared as shown in general experimental procedure.
¹H NMR (400 MHz, CDCl₃) δ 9.80 (d, J = 32.6 Hz, 1H), 8.23 (dd, J = 7.8, 1.8 Hz, 1H), 7.94 (m, 1.5 Hz, 4H), 7.55 – 7.40 (m, 7H), 7.04 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 3.88 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 173.7 (d, J_{C-P} = 7 Hz), 160.0, 137.2 (d, J_{C-P} = 25 Hz), 132.9 (d, J_{C-P} = 126 Hz), 131.8 (d, J_{C-P} = 3 Hz), 131.6 (d, J_{C-P} = 10 Hz), 130.0, 128.5 (d, J_{C-P} = 13 Hz), 123.7, 120.0, 113.6, 55.5.

(E)-N-(4-Cyanobenzylidene)-P,P-diphenylphosphinic amide (7j)⁸




Pale yellow solid; Yield - 69%; R_f (50% EtOAc/hexane) 0.31; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.35 (d, $J = 31.2$ Hz, 1H), 8.09 (d, $J = 8.2$ Hz, 2H), 7.99 – 7.86 (m, 4H), 7.79 (d, $J = 8.2$ Hz, 2H), 7.56 – 7.40 (m, 6H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 171.6 (d, $J_{\text{C-P}} = 8$ Hz), 140.0 (d, $J_{\text{C-P}} = 25$ Hz), 132.6, 132.1, 132.1, 131.5 (d, $J_{\text{C-P}} = 9$ Hz), 130.3, 128.6 (d, $J_{\text{C-P}} = 13$ Hz), 117.9, 116.5.

(E)-*N*-(4-Methylbenzylidene)-*P,P*-diphenylphosphinic amide (7k)⁴




White solid; Yield - 62%; R_f (50% EtOAc/hexane) 0.38; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.28 (d, $J = 32.1$ Hz, 1H), 8.00 – 7.85 (m, 6H), 7.57 – 7.38 (m, 6H), 7.29 (d, $J = 7.9$ Hz, 2H), 2.42 (s, 3H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 173.5 (d, $J_{\text{C-P}} = 7.6$ Hz), 144.6, 133.4 (d, $J_{\text{C-P}} = 24.9$ Hz), 133.2 (d, $J_{\text{C-P}} = 126.4$ Hz), 131.6, 131.5 (d, $J_{\text{C-P}} = 9.1$ Hz), 130.2, 129.6, 128.4 (d, $J_{\text{C-P}} = 12.4$ Hz), 21.8.

(E)-*N*-(3-Methylbenzylidene)-*P,P*-diphenylphosphinic amide (7l)⁷




White solid; Yield - 70%; R_f (50% EtOAc/hexane) 0.3; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.29 (d, $J = 32.4$ Hz, 1H), 7.96–7.91 (m, 4H), 7.83 (s, 1H), 7.79 (t, $J = 4.4$ Hz, 1H), 7.52 – 7.42 (m, 6H), 7.39 (d, $J = 5.2$ Hz, 2H), 2.44 (s, 3H); **$^{13}\text{C NMR}$** (125 MHz, CDCl_3) δ 174.0 (d, $J_{\text{C-P}} = 7.5$ Hz), 138.8, 136.0 (d, $J_{\text{C-P}} = 24.7$ Hz), 134.5, 133.1 (d, $J_{\text{C-P}} = 106.7$ Hz), 131.7, 131.6 (d, $J_{\text{C-P}} = 9.2$ Hz), 130.3, 128.8, 128.4 (d, $J_{\text{C-P}} = 12.5$ Hz), 127.8, 21.3.

(E)-*N*-(2-Methylbenzylidene)-*P,P*-diphenylphosphinic amide (7m)⁷




White solid; Yield - 60%; R_f (50% EtOAc/hexane) 0.35; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.62 (d, $J = 32.6$ Hz, 1H), 8.14 (d, $J = 7.7$ Hz, 1H), 8.02 – 7.90 (m, 4H), 7.53 – 7.41 (m, 7H), 7.36 – 7.21 (m, 2H), 2.68 (s, 3H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 172.5 (d, $J_{\text{C-P}} = 7.6$ Hz), 141.0, 133.7 (d, $J_{\text{C-P}} = 27.8$ Hz), 132.9 (d, $J_{\text{C-P}} = 59.0$ Hz), 131.6 (d, $J_{\text{C-P}} = 9.3$ Hz), 131.5, 129.8, 128.5 (d, $J_{\text{C-P}} = 12.5$ Hz), 126.4, 19.7.

(E)-N-([1,1'-Biphenyl]-4-ylmethylen)-P,P-diphenylphosphinic amide (7n)⁹




white solid; Yield - 82%; R_f (50% EtOAc/hexane) 0.4; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.37 (d, $J = 32.0$ Hz, 1H), 8.09 (d, $J = 8.3$ Hz, 2H), 7.97 (m, 1.4 Hz, 4H), 7.73 (d, $J = 8.3$ Hz, 2H), 7.68 – 7.61 (m, 2H), 7.55 – 7.36 (m, 9H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 173.2 (d, $J_{\text{C-P}} = 7.6$ Hz), 146.4, 139.9, 134.7 (d, $J_{\text{C-P}} = 25$ Hz), 133.0 (d, $J_{\text{C-P}} = 126.5$ Hz), 131.8 (d, $J_{\text{C-P}} = 2$ Hz), 131.6 (d, $J_{\text{C-P}} = 9$ Hz), 130.7, 129.0, 128.5 (d, $J_{\text{C-P}} = 20$ Hz), 128.3, 127.6, 127.3.

(E)-N-(Naphthalen-2-ylmethylen)-P,P-diphenylphosphinic amide (7o)⁷




White solid; Yield - 83%; R_f (50% EtOAc/hexane) 0.4; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.47 (d, $J = 31.9$ Hz, 1H), 8.34 (s, 1H), 8.22 (dd, $J = 8.6, 1.5$ Hz, 1H), 8.03 – 7.86 (m, 7H), 7.65 – 7.54 (m, 2H), 7.54 – 7.43 (m, 6H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 173.7 (d, $J_{\text{C-P}} = 7.6$ Hz), 136.1, 134.4, 133.7, 132.9, 132.4, 131.8, 131.6 (d, $J_{\text{C-P}} = 10$ Hz), 129.4, 128.9, 128.7, 128.5 (d, $J_{\text{C-P}} = 12.5$ Hz), 128.0, 126.9, 123.8.

(E)-N-(2-Bromobenzylidene)-P,P-diphenylphosphinic amide (7p)⁴



Colorless oil; Yield - 78%; R_f (50% EtOAc/hexane) 0.45; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.65 (d, $J = 31.2$ Hz, 1H), 8.29 (dd, $J = 7.4, 2.2$ Hz, 1H), 8.01 – 7.88 (m, 4H), 7.63 (m, 1H), 7.55 – 7.35 (m, 8H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 172.7 (d, $J_{\text{C-P}} = 6.3$ Hz), 134.6 (d, $J_{\text{C-P}} = 25$ Hz), 134.1 (d, $J_{\text{C-P}} = 74$ Hz), 133.3, 132.0, 131.9 (d, $J_{\text{C-P}} = 2$ Hz), 131.6 (d, $J_{\text{C-P}} = 9$ Hz), 129.8, 128.5 (d, $J_{\text{C-P}} = 13$ Hz), 128.0, 127.6.

(E)-N-(3,4-Dimethoxybenzylidene)-P,P-diphenylphosphinic amide (7q)⁶




White solid; Yield - 58%; R_f (50% EtOAc/hexane) 0.13; Prepared as shown in general experimental procedure. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 9.18 (d, $J = 32.0$ Hz, 1H), 7.93 -7.88 (m, 4H), 7.61 (s, 2H), 7.49-7.43 (m, 6H), 6.92 (d, $J = 8.1$ Hz, 1H), 3.95 (s, 3H), 3.92 (s, 3H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 172.9 (d, $J_{\text{C-P}} = 7.1$ Hz), 154.0, 149.5, 133.1 (d, $J_{\text{C-P}} = 127.5$ Hz), 131.6, 131.5, 131.4, 129.1 (d, $J_{\text{C-P}} = 25.3$ Hz), 128.4 (d, $J_{\text{C-P}} = 12.4$ Hz), 126.8, 110.2 (d, $J_{\text{C-P}} = 62.7$ Hz), 56.0, 56.0.

General procedure for Synthesis of Aziridine:


To a flame-dried schlenk tube containing K_2CO_3 (67.9 mg, 0.49 mmol), *O*-benzyl(Thiolan-2-yl)diphenylmethyl ether (11.2 mg, 0.03 mmol), NaI (13 mg, 0.08 mmol), imine (50 mg, 0.16 mmol) and 0.5 ml of CH_3CN were added. To that, finally benzyl bromide (38.9 μL , 0.33 mmol) was added and stirred, the reaction was monitored by TLC. After completion, the reaction mixture was diluted with EtOAc and filtered through Celite[®], filtrate was evaporated in *vacuo* to yield the crude product. The crude product was further purified by EtOAc/hexane mixture over neutral alumina to afford the pure corresponding product.

(2*R*,3*R*)-2,3-Diphenyl-1-tosylaziridine (8a)¹⁰




White solid; Yield - 78%; R_f (20% EtOAc/hexane) 0.5; Prepared as shown in general experimental procedure. $[\alpha]^{27}_D = +23.8$ (c 0.92, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.63 (d, $J = 8.4$ Hz, 2H), 7.43 – 7.34 (m, 10H), 7.21 – 7.19 (m, 2H), 4.27 (s, 2H), 2.39 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 143.9, 137.1, 133.0, 129.4, 128.7, 128.5, 127.5, 128.3, 50.4, 21.6; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1); retention time: 17.4 min (enantiomer) and 20.7 min (major).

***tert*-butyl (2*R*,3*R*)-2,3-Diphenylaziridine-1-carboxylate (8b)¹¹**




White solid; Yield - 63%; R_f (5% EtOAc/hexane) 0.3; Prepared as shown in general experimental procedure. $[\alpha]^{27}_D = +121$ (c 1.0, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.32 – 7.30 (m, 10H), 3.78 (s, 2H), 1.20 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 159.4, 135.6, 128.5, 128.1, 127.1, 81.4, 47.6, 27.7; enantioselectivity was determined by HPLC analysis (Chiraldak-AD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19/1); retention time: 8.1 min (major) and 8.8 min (enantiomer).

((2*R*,3*R*)-2,3-Diphenylaziridin-1-yl)diphenylphosphine oxide (8c)¹²




White solid; Yield - 85%; R_f (50% EtOAc/hexane) 0.59; Prepared as shown in general experimental procedure. $[\alpha]^{27}_D = -17.3$ (c 0.82, CHCl_3); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.85 (m, 2H), 7.64 – 7.55 (m, 2H), 7.40 – 7.19 (m, 16H), 4.09 (d, $J = 12$ Hz, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 135.6 (d, $J_{\text{C-P}} = 5$ Hz), 131.7 (d, $J_{\text{C-P}} = 9$ Hz), 131.3 (d, $J_{\text{C-P}} = 4$ Hz), 128.3, 128.2, 128.1, 128.0, 127.8, 47.2 (d, $J_{\text{C-P}} = 6$ Hz); enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1); retention time: 20.0 min (major) and 23.4 min (enantiomer).

((2*R*,3*R*)-2-Phenyl-3-(4-(trifluoromethyl)phenyl)aziridin-1-yl)diphenylphosphine oxide (8d)




White solid; Yield - 82%; R_f (50% EtOAc/hexane) 0.63; Prepared as shown in general experimental procedure. Mp 124-126 °C; $[\alpha]^{27}_D = -11.3$ (c 1.0, CHCl₃); **IR** (neat): 3057, 1494, 1437, 1203, 1123, 1014, 956, 727, 708, 555 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.93 – 7.83 (m, 2H), 7.67 – 7.57 (m, 2H), 7.50 (q, J = 8.6 Hz, 4H), 7.45 – 7.32 (m, 6H), 7.32 – 7.23 (m, 5H), 4.15 (q, J = 3.2 Hz, 1H), 4.11 (q, J = 3.2 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 139.7 (d, J_{C-P} = 1.9 Hz), 135.0 (d, J_{C-P} = 5.0 Hz), 134.0 (d, J_{C-P} = 133.3 Hz), 132.5 (d, J_{C-P} = 124 Hz), 131.6, 131.5, 131.4, 131.3, 130.1 (q, J_{C-F} = 32.3 Hz), 128.3, 128.2, 128.1, 128.0, 127.7, 124.0 (d, J_{C-F} = 270.5 Hz), 125.1 (d, J_{C-P} = 3.4 Hz), 122.6, 47.4 (d, J_{C-P} = 6.7 Hz), 46.4 (d, J_{C-P} = 6.6 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.24; **EI-MS** (m/z): Calcd for C₂₇H₂₂F₃NOP [(M + H)⁺] 464.1391, found [(M + H)⁺] 464.1405; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1); retention time: 15.9 min (major) and 20.8 min (enantiomer).

((2*R*,3*R*)-2-(4-Chlorophenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8e)




White solid; Yield - 84%; R_f (50% EtOAc/hexane) 0.6; Prepared as shown in general experimental procedure. Mp 137-140 °C; $[\alpha]^{27}_D = -36.7$ (c 1.0, CHCl₃); **IR** (neat): 3060, 1619, 1438, 1325, 1166, 1124, 729, 697, 558 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.89-7.83 (m, 2H), 7.65-7.60 (m, 2H), 7.44 – 7.19 (m, 15H), 4.10 (dd, J = 14.3, 3.2 Hz, 1H), 4.03 (dd, J = 14.0, 3.2 Hz, 1H); **¹³C NMR** (125 MHz, CDCl₃) δ 135.4 (d, J_{C-P} = 4.7 Hz), 134.1 (d, J_{C-P} = 133.1 Hz), 134.0 (d, J_{C-P} = 5.5 Hz), 132.7 (d, J_{C-P} = 124.2 Hz), 131.6, 131.4 (d, J_{C-P} = 13 Hz), 131.3, 129.6, 129.2, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.6, 46.8, 46.8; **³¹P NMR** (162 MHz, CDCl₃) δ 28.24; **EI-MS** (m/z): Calcd for C₂₆H₂₂ClNOP [(M + H)⁺] 430.1128, found [(M + H)⁺] 430.1122; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1); retention time: 19.1 min (major) and 24.7 min (enantiomer).

((2*R*,3*R*)-2-(4-Fluorophenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8f)




White solid; Yield - 85%; R_f (50% EtOAc/hexane) 0.58; Prepared as shown in general experimental procedure. Mp 139–141 °C; $[\alpha]^{27}_D = -24.7$ (c 1.0, CHCl₃); **IR** (neat): 3058, 1604, 1512, 1205, 1123, 957, 726, 694, 526 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.92 – 7.81 (m, 2H), 7.63 (m, 2H), 7.48 – 7.22 (m, 13H), 6.98 – 6.89 (m, 2H), 4.15 (dd, J = 14.5, 3.3 Hz, 1H), 4.01 (dd, J = 14.0, 3.3 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 162.5 (d, J_{C-F} = 245.2 Hz), 135.6 (d, J_{C-P} = 4.8 Hz), 134.2 (d, J_{C-P} = 133.2 Hz), 132.8 (d, J_{C-P} = 124.2 Hz), 131.5 (d, J_{C-P} = 31.9 Hz), 131.5 (d, J_{C-P} = 13.2 Hz), 131.0, 129.7 (d, J_{C-P} = 8.2 Hz), 128.3, 128.3, 128.2, 128.1, 128.0 (d, J_{C-P} = 2.8 Hz), 127.5, 115.20, 115.0, 47.2 (d, J_{C-P} = 7 Hz), 46.3 (d, J_{C-P} = 6.4 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.20; **EI-HRMS** (*m/z*): Calcd for C₂₆H₂₁FNOP [(M)⁺] 413.1345, found [(M)⁺] 413.1353; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19/1); retention time: 8.1 min (major) and 10.1 min (enantiomer).

((2*R*,3*R*)-2-(4-Methoxyphenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8g)




Colorless oil; Yield - 86%; R_f (50% EtOAc/hexane) 0.55; Prepared as shown in general experimental procedure. $[\alpha]^{28}_D = -210.0$ (c 0.4, CHCl₃); **IR** (neat): 3057, 2995, 2926, 1612, 1514, 1438, 1248, 1170, 1125, 742, 558 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.90 – 7.81 (m, 2H), 7.67 – 7.58 (m, 2H), 7.43 – 7.22 (m, 13H), 6.81 – 6.75 (m, 2H), 4.17 (dd, J = 14.6, 3.3 Hz, 1H), 3.99 (dd, J = 14.1, 3.3 Hz, 1H), 3.79 (s, 3H); **¹³C NMR** (125 MHz, CDCl₃) δ 159.4, 136.1 (d, J_{C-P} = 4.5 Hz), 134.5 (d, J_{C-P} = 133.1 Hz), 133.1 (d, J_{C-P} = 124.4 Hz), 131.7 (d, J_{C-P} = 9.1 Hz), 131.5, 131.4, 131.3, 129.3, 128.3, 128.2, 128.0, 127.9 (d, J_{C-P} = 9.3 Hz), 127.5, 127.1 (d, J_{C-P} = 5.1 Hz), 113.6, 55.2, 47.9 (d, J_{C-P} = 6.9 Hz), 46.0 (d, J_{C-P} = 6.2 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.24; **HRMS (FAB⁺, magnetic sector)** (*m/z*): Calcd for C₂₇H₂₅NO₂P [(M + H)⁺] 426.1623, found [(M + H)⁺] 426.1628; enantioselectivity was determined by HPLC analysis (Chiralcel-OD-H, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 9/1); retention time: 7.9 min (major) and 9.7 min (enantiomer).

((2*R*,3*R*)-2-(3-Methoxyphenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8h)




White solid; Yield - 93%; R_f (50% EtOAc/hexane) 0.55; Prepared as shown in general experimental procedure. Mp 156–158 °C; $[\alpha]^{28}_D = -2.3$ (c 0.7, CHCl₃); **IR** (neat): 3057, 3005, 2833, 1602, 1438, 1206, 1123, 958, 727, 548 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 7.89 – 7.73 (m, 2H), 7.61 (m, 2H), 7.37 – 7.21 (m, 11H), 7.14 (t, J = 7.9 Hz, 1H), 6.94 – 6.76 (m, 2H), 6.75 (dd, J = 8.2, 1.6 Hz, 1H), 4.08 (dd, J = 14.2, 3.1 Hz, 1H), 4.02 (dd, J = 14.1, 3.1 Hz, 1H), 3.72 (s, 3H); **¹³C NMR** (125 MHz, CDCl₃) δ 159.6, 137.4 (d, J_{C-P} = 4.7 Hz), 135.4 (d, J_{C-P} = 4.7 Hz), 134.5 (d, J_{C-P} = 133.5 Hz), 133.0 (d, J_{C-P} = 124.4 Hz), 131.7 (d, J_{C-P} = 9.1 Hz), 131.5, 131.4, 131.3, 129.3, 128.3, 128.2, 128.0, 128.0, 127.9, 120.1, 114.1, 112.8, 55.2, 47.6 (d, J_{C-P} = 6.9 Hz), 47.0 (d, J_{C-P} = 6.6 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.12; **HREI-MS** (m/z): Calcd for C₂₇H₂₄NO₂P [(M)⁺] 425.1545, found [(M)⁺] 425.1554; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 254 nm, hexane/i-PrOH, 49:1); retention time: 24.0 min (major) and 26.6 min (enantiomer).

((2*R*,3*R*)-2-(2-Methoxyphenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8i)




Colorless oil; Yield - 88%; R_f (50% EtOAc/hexane) 0.43; Prepared as shown in general experimental procedure. $[\alpha]^{28}_D = +9.9$ (c 0.1, CHCl₃); **IR** (neat): 3057, 2953, 2837, 1603, 1588, 1463, 1438, 1248, 1200, 1124, 1027, 9924, 753, 727, 697, 565 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.91 – 7.91 (m, 2H), 7.71 – 7.66 (m, 2H), 7.46 – 7.21 (m, 13H), 6.94 (m, 1H), 6.66 (m, 1H), 4.32 (dd, J = 14.4, 3.2 Hz, 1H), 4.20 (dd, J = 14.8, 3.2 Hz, 1H), 3.60 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 158.9, 136.4 (d, J_{C-P} = 4.8 Hz), 134.7 (d, J_{C-P} = 131.9 Hz), 133.2 (d, J_{C-P} = 125.1 Hz), 131.6 (d, J_{C-P} = 8.9 Hz), 131.3, 131.0, 129.2, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 123.6, 123.5, 120.1, 109.7, 54.7, 44.6 (d, J_{C-P} = 5.8 Hz), 44.7 (d, J_{C-P} = 6.9 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.26; **HREI-MS** (m/z): Calcd for C₂₇H₂₄NO₂P [(M)⁺] 425.1545, found [(M)⁺] 425.1543; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 280 nm, hexane/i-PrOH, 9:1); retention time: 6.0 min (major) and 7.3 min (enantiomer).

(4-((2*R*,3*R*)-1-(Diphenylphosphoryl)-3-phenylaziridin-2-yl)benzonitrile (8j)¹³




White solid; Yield - 73%; R_f (50% EtOAc/hexane) 0.35; Prepared as shown in general experimental procedure. Mp 184-186 °C; $[\alpha]^{28}_D = -10.7$ (*c* 1.0, CHCl₃); **IR** (neat): 3058, 2227, 1609, 1438, 1205, 1123, 953, 727, 694, 552 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.88 – 7.80 (m, 2H), 7.66 – 7.63 (m, 2H), 7.58 – 7.23 (m, 15H), 4.12 (q, *J* = 3.2 Hz, 1H), 4.08 (q, *J* = 3.2 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 141.0 (d, *J*_{C-P} = 5.3 Hz), 134.8 (d, *J*_{C-P} = 4.8 Hz), 133.8 (d, *J*_{C-P} = 133 Hz), 132.3 (d, *J*_{C-P} = 123 Hz), 132.0, 131.7, 131.6 (d, *J*_{C-P} = 2.8 Hz), 131.5 (d, *J*_{C-P} = 9.4 Hz), 131.3 (d, *J*_{C-P} = 9.4 Hz), 128.5, 128.3 (d, *J*_{C-P} = 21.8 Hz), 128.4, 128.3, 128.1, 127.6, 118.6, 111.7, 47.5 (d, *J*_{C-P} = 6.5 Hz), 46.5 (d, *J*_{C-P} = 6.6 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.35; **HRMS (FAB⁺, magnetic sector) (*m/z*):** Calcd for C₂₇H₂₂N₂OP [(M + H)⁺] 421.1470, found [(M + H)⁺] 421.1463; enantioselectivity was determined by HPLC analysis (Chiralpak-AS, 0.7 mL/min, 254 nm, hexane/*i*-PrOH, 19:1); retention time: 32.6 min (major) and 38.7 min (enantiomer).

((2*R*,3*R*)-2-Phenyl-3-(p-tolyl)aziridin-1-yl)diphenylphosphine oxide(8k)




White solid; Yield - 85%; R_f (50% EtOAc/hexane) 0.63; Prepared as shown in general experimental procedure. Mp 152-154 °C; $[\alpha]^{27}_D = -24.3$ (*c* 1.0, CHCl₃); **IR** (neat): 3056, 2917, 1517, 1437, 1261, 1069, 725, 695, 572 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.89 – 7.84 (m, 2H), 7.66 – 7.61 (m, 2H), 7.41 – 7.24 (m, 13H), 7.07 (d, *J* = 7.9 Hz, 2H), 4.09 (dt, *J* = 12.9, 3.3 Hz, 2H), 2.32 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 137.7, 135.8 (d, *J*_{C-P} = 4.3 Hz), 135.1, 133.8 (d, *J*_{C-P} = 10.9 Hz), 132.4, 131.7 (d, *J*_{C-P} = 9.2 Hz), 131.5, 131.4, 131.3 (d, *J*_{C-P} = 1.5 Hz), 128.9, 128.3, 128.2, 128.2, 128.1, 127.9 (d, *J*_{C-P} = 1.9 Hz), 127.7 (d, *J*_{C-P} = 3.5 Hz), 47.3 (d, *J*_{C-P} = 6.9 Hz), 46.8 (d, *J*_{C-P} = 6.7 Hz), 21.2; **³¹P NMR** (162 MHz, CDCl₃) δ 28.20; **EI-MS (*m/z*):** Calcd for C₂₇H₂₅NOP [(M + H)⁺] 410.1674, found 410.1686; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49:1); retention time: 18.1 min (major) and 22.9min (enantiomer).

((2*R*,3*R*)-2-Phenyl-3-(m-tolyl)aziridin-1-yl)diphenylphosphine oxide (8l)




White solid; Yield - 92%; R_f (50% EtOAc/hexane) 0.55; Prepared as shown in general experimental procedure. Mp 152–154 °C; $[\alpha]^{30}_D = -9.0$ (c 0.3, CHCl₃); **IR** (neat): 3057, 3009, 2978, 2917, 1605, 1590, 1438, 1206, 955, 779, 712, 552 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 7.93 – 7.84 (m, 2H), 7.67 – 7.59 (m, 2H), 7.42 – 7.25 (m, 11H), 7.18–7.14 (m, 2H), 7.12 (s, 1H), 7.06 (d, $J = 6.5$ Hz, 1H), 4.10 (dq, $J = 6.5$ Hz, 2H), 2.29 (s, 3H); **¹³C NMR** (125 MHz, CDCl₃) δ 137.8, 135.7 (d, $J_{C-P} = 5.0$ Hz), 135.5 (d, $J_{C-P} = 4.8$ Hz), 134.5 (d, $J_{C-P} = 134.1$ Hz), 133.0 (d, $J_{C-P} = 125.1$ Hz), 131.7 (d, $J_{C-P} = 9.2$ Hz), 131.5, 131.4, 131.2, 128.7 (d, $J_{C-P} = 5.9$ Hz), 128.3, 128.2, 128.2, 128.1, 128.0, 127.9, 127.8, 124.7, 47.2 (d, $J_{C-P} = 6.6$ Hz), 47.0 (d, $J_{C-P} = 6.7$ Hz), 21.3; **³¹P NMR** (162 MHz, CDCl₃) δ 28.02; **EI-MS** (m/z): Calcd for C₂₇H₂₄NOP [(M)⁺] 409.1596, found [(M)⁺] 409.1595; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH 49/1); retention time: 16.5 min (major) and 19.6 min (enantiomer).

((2*R*,3*R*)-2-Phenyl-3-(o-tolyl)aziridin-1-yl)diphenylphosphine oxide (8m)




Colorless oil; Yield - 86%; R_f (50% EtOAc/hexane) 0.6; Prepared as shown in general experimental procedure. $[\alpha]^{28}_D = -7.4$ (c 1.0, CHCl₃); **IR** (neat): 3057, 1604, 1490, 1456, 1206, 1123, 957, 751, 727, 555 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.97 – 7.88 (m, 2H), 7.65 – 7.57 (m, 2H), 7.45 – 7.33 (m, 7H), 7.31 – 7.22 (m, 5H), 7.21 – 7.15 (m, 2H), 7.04 (m, 1H), 4.29 (dd, $J = 15.0, 3.5$ Hz, 1H), 4.00 (dd, $J = 14.3, 3.5$ Hz, 1H), 2.13 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 137.7, 135.2 (d, $J_{C-P} = 5.5$ Hz), 134.3 (d, $J_{C-P} = 132.3$ Hz), 134.0 (d, $J_{C-P} = 4.7$ Hz), 132.7 (d, $J_{C-P} = 124.4$ Hz), 131.7, 131.6 (d, $J_{C-P} = 4.2$ Hz), 131.5, 131.3 (d, $J_{C-P} = 1.7$ Hz), 129.8, 128.3, 128.2, 128.0, 127.9, 127.9, 127.8, 126.4, 125.8, 46.8 (d, $J_{C-P} = 6.7$ Hz), 44.5 (d, $J_{C-P} = 6.4$ Hz), 19.1; **³¹P NMR** (162 MHz, CDCl₃) δ 28.40; **EI-MS** (m/z): Calcd for C₂₇H₂₅NOP [(M + H)⁺] 410.1674, found [(M + H)⁺] 410.1665; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49:1); retention time: 14.6 min (major) and 18.4 min (enantiomer).

((2*R*,3*R*)-2-([1,1'-Biphenyl]-4-yl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8n)




White solid; Yield - 82%; R_f (50% EtOAc/hexane) 0.48; Prepared as shown in general experimental procedure. Mp 110-113 °C; $[\alpha]^{27}_D = -17.6$ (*c* 1.0, CHCl₃); **IR** (neat): 3056, 3030, 1600, 1438, 1205, 1124, 998, 727, 694, 555 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.93 – 7.88 (m, 2H), 7.67 – 7.57 (m, 4H), 7.51 – 7.25 (m, 18H), 4.18 (dd, *J* = 14.3, 3.3 Hz, 1H), 4.12 (dd, *J* = 14.1, 3.3 Hz, 1H); **¹³C NMR** (125 MHz, CDCl₃) δ 140.8, 140.7, 135.7 (d, *J*_{C-P} = 4.9 Hz), 134.5 (d, *J*_{C-P} = 5.0 Hz), 134.4 (d, *J*_{C-P} = 133.2 Hz), 132.9 (d, *J*_{C-P} = 124.25 Hz), 131.7, 131.6, 131.5, 131.4, 131.3, 128.8, 128.3, 128.3, 128.0, 128.0, 127.7, 127.3, 127.0, 126.9, 47.3 (d, *J*_{C-P} = 6.6 Hz), 47.0 (d, *J*_{C-P} = 6.6 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.32; **HRMS (FAB⁺, magnetic sector)** (*m/z*): Calcd for C₃₂H₂₇NOP [(M + H)⁺] 472.1830, found [(M + H)⁺] 472.1826; enantioselectivity was determined by HPLC analysis (Chiralpak-AD-H, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 3/1); retention time: 33.0 min (major) and 60.0 min (enantiomer).

((2*R*,3*R*)-2-(Naphthalen-2-yl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8o)




White solid; Yield - 86%; R_f (50% EtOAc/hexane) 0.63; Prepared as shown in general experimental procedure. Mp 169-171 °C; $[\alpha]^{27}_D = -22.7$ (*c* 1.0, CHCl₃); **IR** (neat): 3049, 1438, 1205, 1162, 1124, 964, 728, 695, 559 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.95 – 7.86 (m, 2H), 7.84 – 7.71 (m, 4H), 7.68 – 7.58 (m, 2H), 7.52 (m, 1H), 7.50 – 7.20 (m, 13H), 4.31 (dd, *J* = 14.2, 3.2 Hz, 1H), 4.21 (dd, *J* = 14.1, 3.2 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 135.4 (d, *J*_{C-P} = 5.5 Hz), 134.3 (d, *J*_{C-P} = 133.2 Hz), 133.1 (d, *J*_{C-P} = 5.1 Hz), 133.0, 133.0, 132.8 (d, *J*_{C-P} = 124.4 Hz), 131.7, 131.6, 131.5, 131.4, 128.3, 128.2, 128.2, 128.0, 128.0, 127.9, 127.9, 127.6, 127.5, 126.1, 126.0, 124.9, 47.4 (d, *J*_{C-P} = 6.8 Hz), 47.2 (d, *J*_{C-P} = 6.7 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.18; **HRMS (FAB⁺, magnetic sector)** (*m/z*): Calcd for C₃₀H₂₅NOP [(M + H)⁺] 446.1674, found [(M + H)⁺] 446.1673; enantioselectivity was determined by HPLC analysis (Chiralcel- OD-H, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19/1); retention time: 14.7 min (major) and 17.2 min (enantiomer).

((2*R*,3*R*)-2-(2-Bromophenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8p)




White solid; Yield - 82%; R_f (50% EtOAc/hexane) 0.5; Prepared as shown in general experimental procedure. Mp 94–96 °C; $[\alpha]^{30}_D = +28.2$ (c 0.3, CHCl₃); **IR** (neat): 3057, 1590, 1497, 1252, 1123, 959, 752, 727, 694, 551, 528 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 7.90 – 7.86 (m, 2H), 7.64 – 7.60 (m, 2H), 7.44 (m, 1H), 7.40 – 7.19 (m, 13H), 7.09 (m, 1H), 4.51 (dd, J = 15.0, 3.5 Hz, 1H), 3.90 (dd, J = 14, 3.5 Hz, 1H); **¹³C NMR** (125 MHz, CDCl₃) δ 135.5 (d, J_{C-P} = 4.9 Hz), 134.6 (d, J_{C-P} = 5.4 Hz), 134.3 (d, J_{C-P} = 133 Hz), 132.5 (d, J_{C-P} = 125 Hz), 131.7, 131.6, 131.6, 131.5, 131.5, 129.3, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0, 127.3, 124.9, 47.8 (d, J_{C-P} = 6.6 Hz), 45.8 (d, J_{C-P} = 6.0 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.61; **HRMS (FAB⁺, magnetic sector) (*m/z*):** Calcd for C₂₆H₂₂NOBrP [(M + H)⁺] 474.0622, found [(M + H)⁺] 474.0620; enantioselectivity was determined by HPLC analysis (Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1); retention time: 18.0 min (major) and 20.2 min (enantiomer).

(2*R*,3*R*)-2-(3,4-Dimethoxyphenyl)-3-phenylaziridin-1-yl)diphenylphosphine oxide (8q)




Colorless oil; Yield - 73%; R_f (50% EtOAc/hexane) 0.59; Prepared as shown in general experimental procedure. $[\alpha]^{30}_D = +26.9$ (c 0.5, CHCl₃); **IR** (neat): 3058, 2934, 2835, 1591, 1517, 1462, 1201, 1108, 1027, 727, 696, 551 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.90 – 7.86 (m, 2H), 7.67 – 7.63 (m, 2H), 7.42 – 7.24 (m, 11H), 6.92 – 6.90 (m, 2H), 6.75 (m, 1H), 4.20 (d, J = 4 Hz, 1H), 4.17 (d, J = 4 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 148.8 (d, J_{C-P} = 21.9 Hz), 136.2, 134.5 (d, J_{C-P} = 133.5 Hz), 133.1 (d, J_{C-P} = 124 Hz), 131.7 (d, J_{C-P} = 9.1 Hz), 131.4 (d, J_{C-P} = 8.6 Hz), 131.4, 131.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.6, 127.4, 120.6, 111.3, 110.8, 55.9, 55.8, 48.7 (d, J_{C-P} = 7.3 Hz), 45.9 (d, J_{C-P} = 6.1 Hz); **³¹P NMR** (162 MHz, CDCl₃) δ 28.14; **EI-MS (*m/z*):** Calcd for C₂₈H₂₆NO₃P [(M)⁺] 455.1650, found [(M)⁺] 455.1649; enantioselectivity was determined by HPLC analysis (Chiralcel-OD-H, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19/1); retention time: 27.5 min (major) and 34.1 min (enantiomer).

(2*R*,3*R*)-2,3-Diphenylaziridine (9)¹⁴



To a suspension of LiAlH₄ (7.7 mg, 0.20 mmol) in THF (0.2 mL) under nitrogen at 0 °C, a solution of aziridine **8c** (26.5 mg, 0.07 mmol) in THF (0.75 mL) was added dropwisely. The mixture was gradually warmed to room temperature and followed by TLC. The reaction mixture was quenched with sat. NH₄Cl, extracted with EtOAc (5 mL x 3), dried over Na₂SO₄, and concentrated in *vacuo*. The residue was purified by flash column chromatography (EtOAc-hexane, 1:9) to give **9** as a colorless liquid (9.2 mg, 69 % yield); *R*_f (30% EtOAc/hexane) 0.57; [α]²⁷_D = +333 (*c* 0.75, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.26 (m, 10H), 3.10 (br s, 2H).

(1*S*,2*R*)-2-Amino-1,2-diphenylethan-1-ol (10)¹⁵





To a stirred solution of aziridine **9** (9.2 mg, 0.05 mmol) in acetone/water (2:1, 0.47 mL) was added trifluoroacetic acid (4 µL, 0.05 mmol) at 10 °C. The mixture was gradually warmed to room temperature and stirred overnight. The reaction mixture was quenched with sat. NaHCO₃, extracted with dichloromethane (5 mL x 3), dried over Na₂SO₄, and concentrated in *vacuo*. The residue was purified by flash column chromatography (EtOAc-hexane, 3:2) to give **10** as a white solid (8 mg, 81 % yield). *R*_f (EtOAc) 0.2; [α]²⁷_D = +6.5 (*c* 0.74, EtOH); ¹H NMR (400 MHz, CDCl₃) 7.33 – 7.21 (m, 10H), 4.75 (d, *J* = 6.3 Hz, 1H), 4.17 (d, *J* = 6.3 Hz, 1H). ee was determined by ¹H NMR of the Mosher amide derivative δ 5.36 (enantiomer), δ 5.29 (major).


References:


1. Wu, H. Y.; Chang, C. W.; Chein, R. J. *J. Org. Chem.* **2013**, *78*, 5788-93.
2. Wang, Z.-X.; Tu, Y.; Frohn, M.; Zhang, J.-R.; Shi, Y. *J. Am. Chem. Soc.* **1997**, *119*, 11224-11235.
3. Vyas, V. J., Fröhlich, R.; Oestreich, M. *Org Lett* **2011**, *13*, 2094-2097.
4. Lauzon, C.; Desrosiers, J. N.; Charette, A. B. *J. Org. Chem.* **2005**, *70*, 10579-80.
5. Banerjee, S.; Groeper, J. A.; Standard, J. M.; Hitchcock, S. R. *Tetrahedron: Asymmetry* **2009**, *20*, 2154-2161.
6. Kinoshita, H.; Ingham, O. J.; Ong, W. W.; Beeler, A. B.; John A. Porco , J. *J. Am. Chem. Soc.* **2012**, *132*, 6412-6418.
7. Boezio, A. A.; Pytkowicz, J.; Cote, A.; Charette, A. B. *J. Am. Chem. Soc.* **2003**, *125*, 14260-1.
8. Yukawa, T.; Seelig, B.; Xu, Y.; Morimoto, H.; Matsunaga, S.; Berkessel, A.; Shibasaki, M. *J. Am. Chem. Soc.* **2010**, *132*, 11988-11992.
9. Pinho, P.; Andersson, P. G. *Tetrahedron* **2001**, *57*, 1615-1618.
10. Illa, O.; Arshad, M.; Ros, A.; McGarrigle, E. M.; Aggarwal, V. K. *J. Am. Chem. Soc.* **2010**, *132*, 1828-1830.
11. Aggarwal, V. K.; Alonso, E.; Fang, G; Ferrara, M.; Hynd, G; Porcelloni, M. *Angew. Chem. Int. Ed.* **2001**, *40*, 1433-1436.
12. Aggarwal, V. K.; Ferrara, M.; O'Brien, C. J.; Thompson, A.; Jones, R. V. H.; Fieldhouse, R. *J. Chem. Soc., Perkin Trans. 1* **2001**, 1635-1643.
13. Appel, R.; Mayr, H. *J. Am. Chem. Soc.* **2011**, *133*, 8241-8250.
14. Ritzen, B.; van Oers, M. C. M.; van Delft, F. L.; Rutjes, F. P. J. T. *J. Org. Chem.* **2009**, *74*, 7548-7551.
15. Gunderson, K. G.; Shapiro, M. J.; Doti, R. A.; Skiles, J. W. *Tetrahedron: Asymmetry* **1999**, *10*, 3263-3266.


HPLC analysis

 6a	HPLC condition: Chiralcel-OJ column, 1.0 mL/min, 20% <i>i</i> -PrOH/hexane, 220 nm, 18.9 min (enantiomer), 35.6 min (major)
--	---




 1a	HPLC condition: Chiralpak-AD column, 5% <i>i</i> -PrOH/hexane, 220 nm, 6.0 min (enantiomer), 8.5 min (major)
--	--



 8a	HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/ <i>i</i> -PrOH, 49/1, 17.4 min (enantiomer) and 20.7 min (major).
--	---



racemic 8a

#	Time	Area	Height	Width	Area%	Symmetry
1	17.372	9294.4	215.3	0.6717	49.940	0.461
2	20.744	9316.6	203.3	0.7126	50.060	0.603



(R,R)-8a with 97% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	18.321	71	1.7	0.5239	1.734	0.701
2	21.502	4020.5	67.4	0.8959	98.266	0.542





HPLC condition: Chiralpak-AD column, 5 % *i*-PrOH/hexane, 220 nm, 8.1 min (major), 8.8 min (enantiomer)


racemic 8b

#	Time	Area	Height	Width	Area%	Symmetry
1	8.301	5023.3	388.1	0.201	50.238	0.846
2	8.984	4975.7	355.5	0.2153	49.762	0.864

(R,R)-8b with 88% ee


#	Time	Area	Height	Width	Area%	Symmetry
1	8.142	39477.1	2899	0.2129	94.227	0.836
2	8.841	2418.8	166.3	0.2237	5.773	0.874



 8c	HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/ <i>i</i> -PrOH, 49/1, 20.0 min (major) and 23.4 min (enantiomer).
--	---



racemic 8c

#	Time	Area	Height	Width	Area%	Symmetry
1	19.969	20528.7	487.5	0.6453	50.773	0.54
2	23.418	19903.5	392.6	0.7794	49.227	0.531



(R,R)-8c with 98% ee


#	Time	Area	Height	Width	Area%	Symmetry
1	20.016	26297	538.9	0.7493	99.076	0.494
2	24.67	245.1	4.6	0.7128	0.924	0.751



HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1, 15.9 min (major) and 20.8 min (enantiomer).


racemic 8d


#	Time	Area	Height	Width	Area%	Symmetry
1	15.811	14100.6	413	0.5223	50.053	0.594
2	20.836	14070.6	313.5	0.6917	49.947	0.6



(R,R)-8d with 96% ee


#	Time	Area	Height	Width	Area%	Symmetry
1	15.284	5063.9	144	0.5363	98.056	0.483
2	20.724	100.4	2.3	0.5823	1.944	0.764



 8e	<p>HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/<i>i</i>-PrOH, 49/1, 19.1 min (major) and 24.7 min (enantiomer).</p>
---	--



racemic 8e

#	Time	Area	Height	Width	Area%	Symmetry
1	19.141	4890.6	67.9	1.054	50.790	0.47
2	24.633	4738.5	87	0.9082	49.210	0.639



(R,R)-8e with 96% ee


#	Time	Area	Height	Width	Area%	Symmetry
1	18.099	33398.1	536.5	0.8723	98.231	0.307
2	24.614	601.3	10.6	0.8857	1.769	0.77



HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 19/1, 8.1 min (major) and 10.1 min (enantiomer).


racemic 8f


#	Time	Area	Height	Width	Area%	Symmetry
1	8.123	10322.6	636.3	0.2473	50.114	0.661
2	10.029	10275.5	525.4	0.3022	49.886	0.677



(R,R)-8f with 97% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	8.587	10865.4	636.4	0.2612	98.456	0.658
2	10.762	170.4	8.5	0.3063	1.544	0.778




 8g	HPLC condition: Chiralcel-OD-H, 1.0 mL/min, 220 nm, hexane/ <i>i</i> -PrOH, 9/1, 7.9 min (major) and 9.7 min (enantiomer).
--	--



racemic 8g

(R,R)-8g with 97% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	7.918	9384.2	489.2	0.2938	50.039	0.704
2	9.711	9369.7	359.9	0.3998	49.961	0.712



#	Time	Area	Height	Width	Area%	Symmetry
1	7.893	22213.9	1162.5	0.2929	98.533	0.667
2	9.799	330.7	12	0.4203	1.467	0.828





HPLC condition: Chiralcel-OD, 1.0 mL/min, 254 nm, hexane/*i*-PrOH, 49:1, 24.0 min (major) and 26.6 min (enantiomer).


racemic 8h

(R,R)-8h with 96% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	24.014	3560.3	53.4	1.1119	51.572	0.397
2	26.598	3343.3	43.2	1.2898	48.428	0.434

#	Time	Area	Height	Width	Area%	Symmetry
1	25.352	11888.7	228.1	0.8686	98.161	0.549
2	28.889	222.7	3.7	0.9965	1.839	0.603




 8i	HPLC condition: Chiralcel-OD, 1.0 mL/min, 280 nm, hexane/ <i>i</i> -PrOH, 9:1, 6.0 min (major) and 7.3 min (enantiomer).
--	--



racemic 8i

(R, R)-8i with 95% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	5.994	7257.9	594.1	0.1865	50.066	0.57
2	7.323	7238.9	453.9	0.2441	49.934	0.543



#	Time	Area	Height	Width	Area%	Symmetry
1	6.048	1074.9	91.2	0.1795	97.595	0.652
2	7.467	26.5	1.8	0.2243	2.405	0.739





HPLC condition: Chiraldak-AS, 0.7 mL/min, 254 nm, hexane/*i*-PrOH, 19:1, 32.6 min (major) and 38.7 min (enantiomer).


racemic 8j

(R, R)-8j with 95% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	32.58	3343.9	30	1.855	50.190	0.71
2	38.674	3318.6	21.5	2.5773	49.810	0.645

#	Time	Area	Height	Width	Area%	Symmetry
1	31.782	22873.5	201	1.8964	97.429	0.594
2	38.602	603.6	3.5	2.8659	2.571	0.515




	HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/i-PrOH, 49/1, 18.1 min (major) and 22.9min (enantiomer).
---	---



racemic 8k

(R, R)-8k with 96% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	18.15	6467.7	163.4	0.6058	50.441	0.604
2	22.911	6354.5	137.5	0.7112	49.559	0.608



#	Time	Area	Height	Width	Area%	Symmetry
1	16.43	36938.6	910.2	0.6115	97.833	0.441
2	21.295	818	18.8	0.6624	2.167	0.737




HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/i-PrOH 49/1, 16.5 min (major) and 19.6 min (enantiomer).


racemic 8l


(R, R)-8l with 97% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	16.468	26921.2	671.6	0.6056	51.187	0.458
2	19.581	25673.1	570.5	0.689	48.813	0.518



#	Time	Area	Height	Width	Area%	Symmetry
1	16.253	31305.7	808.1	0.5879	98.707	0.465
2	19.733	410.1	10.8	0.573	1.293	0.798




 8m	<p>HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/<i>i</i>-PrOH, 49:1, 14.6 min (major) and 18.4 min (enantiomer).</p>
---	--



racemic 8m

(R,R)-8m with 96% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	14.579	18858	592.2	0.4855	50.186	0.572
2	18.407	18718.1	443.1	0.704	49.814	0.561



#	Time	Area	Height	Width	Area%	Symmetry
1	14.635	11949.8	383.5	0.4736	98.151	0.587
2	18.717	225.1	6	0.5624	1.849	0.789




HPLC condition: Chiralpak-AD-H, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 3/1, 33.0 min (major) and 60.0 min (enantiomer).


racemic 8n


(R,R)-8n with 96% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	33.013	3721.4	55.2	1.0389	50.069	0.866
2	59.96	3711.2	31.6	1.5903	49.931	0.921



#	Time	Area	Height	Width	Area%	Symmetry
1	33.186	3759.9	56.2	1.0348	97.939	0.86
2	59.757	79.1	6.6E-1	2.0123	2.061	0.507




 8o	HPLC condition: Chiralcel- OD-H, 1.0 mL/min, 220 nm, hexane/ <i>i</i> -PrOH, 19/1, 14.7 min (major) and 17.2 min (enantiomer).
--	--



racemic 8o

(R,R)-8o with 97% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	14.746	17058.2	414.1	0.6306	49.633	0.676
2	17.203	17310.5	341.5	0.7754	50.367	0.685



#	Time	Area	Height	Width	Area%	Symmetry
1	14.874	31422.3	746.5	0.7016	98.404	0.639
2	17.635	509.7	10.8	0.7839	1.596	0.946




HPLC condition: Chiralcel-OD, 1.0 mL/min, 220 nm, hexane/*i*-PrOH, 49/1, 18.0 min (major) and 20.2 min (enantiomer).


racemic 8p

(R,R)-8p with 96% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	17.869	2317.2	64.5	0.5532	50.426	0.705
2	20.202	2278.1	57.6	0.6098	49.574	0.708



#	Time	Area	Height	Width	Area%	Symmetry
1	17.72	11607.1	314.9	0.5661	98.148	0.596
2	20.319	219.1	5.6	0.5941	1.852	0.747




	HPLC condition: Chiralcel-OD-H, 1.0 mL/min, 220 nm, hexane/ <i>i</i> -PrOH, 19/1, 27.5 min (major) and 34.1 min (enantiomer).
--	---

racemic 8q

(R,R)-8q with 96% ee

#	Time	Area	Height	Width	Area%	Symmetry
1	27.494	83514	854.1	1.4207	50.260	0.363
2	34.078	82650.7	619.7	1.9161	49.740	0.36



#	Time	Area	Height	Width	Area%	Symmetry
1	27.614	35903.3	382.6	1.564	97.963	0.443
2	34.813	746.6	2.6	4.7474	2.037	0.149

